Filing Flows › Nuo Therapeutics (AURX) › Q1 2026 › vs Q4 2025
Nuo Therapeutics (AURX) Q1 2026 vs Q4 2025 (quarter over quarter)
Nuo Therapeutics's revenue rose $205K (+19%) from $1.1M in Q4 2025 to $1.3M in Q1 2026. The biggest changes: Product +$202K (+20%); License +$3K (+4%).
Nuo Therapeutics, Q1 2026: revenue $1.3M (+169% year over year), operating margin -34.3%, net loss $618K, operating cash flow −$784K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Product | $1.2M | $1.0M | $202K | +20% |
| License | $78K | $75K | $3K | +4% |
| Revenue | $1.3M | $1.1M | $205K | +19% |
| Net loss | $618K | $578K | $40K | +7% |
| Costs & expenses | $1.9M | $1.7M | $244K | +15% |
| Operating costs | $1.7M | $1.7M | $72K | +4% |
| Interest & other, net | $172K | −$1K | $173K | — |
| Cost of revenue | $452K | $408K | $44K | +11% |
| Operating expenses | $1.3M | $1.3M | $28K | +2% |
| Operating cash sources | $830K | $470K | $360K | +77% |
| Depreciation | $22K | $24K | −$2K | -7% |
| Share-based compensation | $24K | $24K | $0 | 0% |
| Cash used in operations | $784K | $423K | $362K | +86% |
| Net loss absorbed | $618K | $578K | $40K | +7% |
| Working capital & other | $212K | −$108K | $320K | — |
Questions
How much did Nuo Therapeutics's revenue grow quarter over quarter in Q1 2026?
Nuo Therapeutics's revenue rose $205K (+19%) from $1.1M in Q4 2025 to $1.3M in Q1 2026.
What drove Nuo Therapeutics's revenue change in Q1 2026?
Product +$202K (+20%); License +$3K (+4%).